Biotechnology

OncoBayes progressing OB-001 to tackle ADC resistance and TKI brain penetration

LONDON, Oct. 7, 2026 /PRNewswire/ -- OncoBayes, a privately held clinical-stage pharmaceutical company, today announced the successful completion of preclinical work with OB-001, demonstrating the product's potential to tackle two major unmet needs in oncology: ADC resistance and the brain pen...

2026-10-07 14:00 2520

Werfen Launches QUANTA Link® 5.0: A Modern, Web-Based Platform for Autoimmune Laboratory Workflow Management

A flexible, browser-based solution, QUANTA Link 5.0 centralizes autoimmune testing workflows. It enhances usability, streamlines workflows, and supports confident decision-making in today's autoimmune laboratories. SAN DIEGO, Oct. 6, 2026 /PRNewswire/ -- Werfen today announced the global launch ...

2026-10-06 20:00 3155

Lundbeck presents Phase Ib data for Lu AF28996 in advanced Parkinson's disease, as Phase II trial begins

* Results from an 18-week, open-label Phase Ib trial of investigational Lu AF28996 in people with advanced Parkinson's disease are being presented at MDS 2026 * The trial provided initial safety and tolerability data for Lu AF28996, with most treatment-emergent adverse events reported as mild...

2026-10-06 14:35 3312

CHANDO Group Presents 20 Research Papers at IFSCC 2026 Congress in Perth

12 years of participation underscore the Group's growing presence in global cosmetics science SHANGHAI and PERTH, Australia, Oct. 6, 2026 /PRNewswire/ -- The 36th Congress of the International Federation of Societies of Cosmetic Chemists (IFSCC) was held in Perth, Australia, from September 28 to...

2026-10-06 11:40 4106

Fapon Showcases High-Performance IVD Raw Materials at JACLaS EXPO 2026

KOBE, Japan, Oct. 6, 2026 /PRNewswire/ -- Fapon, a trusted global IVD provider, will showcase its one-stop IVD solution at JACLaS EXPO 2026, held October 8–10 in Kobe, Japan. Visit Booth B32, Hall 1, 1st Floor. Fapon will spotlight its latest breakthroughs in small molecule sandwich antibodies a...

2026-10-06 08:00 2614

EpiSign and Geneyx Announce Partnership to Integrate Genomic and Epigenomic Analysis for Rare Disease

Collaboration brings EpiSign's comprehensive DNA methylation episignature analysis together with the Geneyx genomic and multi-omics analysis platform LONDON, ON and HERZLIYA, Israel, Oct. 5, 2026 /PRNewswire/ -- EpiSign Inc. and Geneyx Genomex Ltd. today announced a partnership to advance the in...

2026-10-05 21:52 3560

Ajinomoto Bio-Pharma Services Unveils Refreshed Global Brand, Showcasing its Strength in Specialization

* Reflects the depth of expertise and innovation Aji Bio-Pharma brings to customers navigating increasingly demanding development and manufacturing challenges TOKYO, Oct. 5, 2026 /PRNewswire/ -- Ajinomoto Bio-Pharma Services ("Aji Bio-Pharma"), a global network of specialized contract developme...

2026-10-05 19:00 4690

EVIDENT Completes Acquisition of CrestOptics S.p.A.

NEEDHAM, Mass., Oct. 5, 2026 /PRNewswire/ -- Evident announced today that it has completed the acquisition of CrestOptics S.p.A., a Rome-based developer and manufacturer of advanced optical imaging systems for spinning disk confocal and super-resolution microscopy. The acquisition broadens Eviden...

2026-10-05 15:20 2259

AnnJi Pharmaceutical Advances AJ201 into Pivotal Phase 3 ROMA-KD Trial for Spinal and Bulbar Muscular Atrophy (SBMA)

The only known investigational therapy for SBMA in Phase 3 development worldwide * AJ201 (rosolutamide) is an investigational oral small molecule designed to address multiple disease mechanisms of spinal and bulbar muscular atrophy (SBMA, or Kennedy's disease) * Following submission of the Ph...

2026-10-05 12:30 2925

CSL and Alentis announce global partnership to develop and commercialise lixudebart for rare kidney and liver diseases

Alentis to receive US$355 million initial payment and up to US$1.2 billion in commercial milestones, with global profits shared MELBOURNE, Australia and BASEL, Switzerland, Oct. 5, 2026 /PRNewswire/ -- CSL and Alentis Therapeutics today announced they have entered into an exclusive global collab...

2026-10-05 05:46 4159

SIBIONICS and PharmaSens Explore New Horizons for Automated Insulin Delivery at EASD 2026

MILAN, Oct. 4, 2026 /PRNewswire/ -- At the European Association for the Study of Diabetes (EASD) 2026, SiBionics presented "See More, Act Earlier," connecting continuous sensing with future diabetes care. Three exhibition chapters shaped this vision: "See More: Beyond Glucose," covering glucose, ...

2026-10-04 10:47 3195

Antengene to Present Latest Preclinical Results of Novel Cos-TCE Platform in Rapid Oral Abstract Presentation at SITC 2026

SHANGHAI and HONG KONG, Oct. 3, 2026 /PRNewswire/ -- Antengene Corporation Limited ("Antengene", SEHK: 6996.HK), a leading innovative, commercial-stage global biotech company dedicated to discovering, developing and commercializing first-in-class and/or best-in-class medicines for autoimmune dise...

2026-10-03 08:30 10679

Ascletis' ASC36_35FDC Demonstrated Potential for Once-Monthly to Once-Quarterly Dosing and Robust Weight-Loss in Preclinical Studies Presented at EASD 2026

HONG KONG, Oct. 2, 2026 /PRNewswire/ -- Ascletis Pharma Inc. (HKEX: 1672, "Ascletis") today announced the presentation of key preclinical data for its ASC36_35FDC (ASC36_35 co-formulation) at the 62nd European Association for the Study of Diabetes (EASD) Annual Meeting, being held September 28–Oc...

2026-10-02 17:00 4169

Lundbeck to showcase progress across its movement disorders pipeline with data in multiple system atrophy and Parkinson's disease at MDS® 2026

* Late-breaking Phase III MASCOT oral presentation will characterize the clinical profile and diversity of participants in Lundbeck's ongoing global Phase III trial investigating amlenetug in multiple system atrophy (MSA) * New research across clinical trial endpoints, biomarkers, diagnostic t...

2026-10-02 15:05 4228

Emerald Clinical Trials Appoints Michael Stibilj as Chief Executive Officer to Lead Next Phase of Global Growth

SINGAPORE, Oct. 1, 2026 /PRNewswire/ -- Emerald  Clinical Trials

2026-10-01 11:00 5235

The 94th CMEF, the World's Leading Medical Device Industry Event, Set to Open in Beijing Oct. 21-24

BEIJING, Sept. 30, 2026 /PRNewswire/ -- The 94th China International Medical Equipment Fair (CMEF) and concurrent events—including ICMD, covering medical device design and manufacturing; CRS, focusing on rehabilitation and assistive technology; CECN, dedicated to elderly care and nursing; and Hea...

2026-09-30 21:16 1853

Zhendong Pharmaceutical Announces Publication of Phase IIb Study of Investigational Vaginal Lactobacillus Capsule in the National Medical Journal of China

BEIJING, Sept. 30, 2026 /PRNewswire/ -- Zhendong Pharmaceutical announced that results from a multicenter, randomized, double-blind, placebo-controlled Phase IIb study evaluating its investigational Live Double Combined Lactobacillus Capsule for Vaginal Use for the treatmen...

2026-09-30 20:00 1559

43% Improvement in Hair Breakage Resistance. Scalp Redness Down 14%. Singapore's CellResearch Presents Breakthrough Hair Data at AMWC Japan

Two independent laboratory studies on PTT-6®, the cord lining stem cell active from Singapore's CellResearch Corporation, deliver standards-based evidence on hair fiber strength and scalp condition — as the global hair and scalp care category climbs from USD 93.6 billion to USD 150.5 billion by 2...

2026-09-30 17:46 925

Australia's biosolutions sector could nearly triple to AUD$ 13.1 billion by 2035

New report finds the sector could support nearly 44,000 jobs, but stronger incentives are needed to turn Australia's agricultural resources into jobs, resilience and economic value MELBOURNE, Australia, Sept. 30, 2026 /PRNewswire/ -- As Australia seeks to strengthen its domestic supply chain and...

2026-09-30 10:00 2816

Telix Granted FDA Fast Track Designation for BiPASS Pre-Biopsy Prostate Cancer Imaging

* FDA Fast Track designation granted for Telix's BiPASS® program, which is evaluating68Ga-PSMA-PET imaging alongside MRI in the pre-biopsy prostate cancer setting. * The designation recognizes the program's potential to address an important unmet need by enabling an imaging-first approach to ...

2026-09-30 08:26 1966
12345678 ... 186